New vaccine trains immune system to fight tough melanoma
NCT ID NCT07288112
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapy. DOC1021 is a personalized vaccine made from a patient's own blood and tumor cells, designed to teach the immune system to attack the cancer. The trial will first check safety in a small group, then look at whether the treatment can shrink tumors. Participants also receive a drug called peginterferon alfa-2a to boost the immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DOC1021 (personalized dendritic cell vaccine made from the patient's own blood and tumor material) plus peginterferon alfa-2a
What this could lead to
If it works, this could offer a new treatment option for people with melanoma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to everyone. The treatment involves multiple procedures and may cause side effects like flu-like symptoms or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
RECRUITINGGilbert, Arizona, 85234, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Institute
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Southwestern
RECRUITINGDallas, Texas, 75235, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact